Company Overview
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Why Investors Should Care
Return on capital employed stands at 30.3%.
Revenue has grown at a 34.5% CAGR over the past five years.
Trades at a P/E of 2.1, below the sector median of 25.4.
Operating margin of 20.2% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.11.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $294.28M (+64.1% YoY); net profit $367.02M.
- Trailing 12 Months Year-on-year growth — revenue +10.3%, earnings -30.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 34.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 34.53% |
| 1 Year: | 10.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -30.20% |
Stock Price Performance
| 1 Year: | +112.76% |
| 6 Months: | +0.81% |
| 3 Months: | +37.37% |
| 1 Month: | +28.34% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)67.24 · Neutral
P/E of 2.13 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 30.3%.
- Compounding revenue at 34.5% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RIGL Rigel Pharmaceuticals, Inc. R2K | 41.17 | 2.13 | $761.73M | 0.00% | 30.28% | - | 34.53% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 3.58M | - | 900.00K | - | 1.79M | 4.87M | 37.86M | 12.62M | 10.41M | 20.86M | 15.40M | 55.76M | 16.02M | 18.39M | 18.45M | 81.02M | 26.27M | 21.54M | 16.73M | 29.82M | 22.41M | 26.07M | 26.89M | 28.13M | 29.53M | 36.84M | 55.31M | 53.33M | 101.69M | 69.46M | 69.80M | 58.82M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.41M | 4.50M | 4.75M | 5.96M | 4.61M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | 1.76M | 4.80M | 7.11M | 7.95M | 9.86M | 11.41M | 13.65M | 12.53M | 14.70M | 16.15M | 17.43M | - | - | - | - | - | - | - | - | - | - | - | - | 48.92M | 97.18M | 64.71M | 63.85M | 54.21M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 36.15M | 36.08M | 36.29M | 40.68M | 42.33M |
| Operating Income | -25.46M | -21.04M | -18.24M | -13.97M | -6.78M | -17.57M | -13.65M | -22.74M | -16.20M | -19.34M | -17.86M | -24.73M | -26.11M | -24.37M | - | -18.38M | -21.34M | -12.04M | - | 21.03M | -17.39M | -13.78M | - | 41.76M | -13.05M | -19.79M | -26.26M | -12.96M | -18.40M | -12.72M | -5.27M | -4.46M | -6.97M | 447.00K | 14.06M | 12.77M | 61.10M | 28.42M | 23.17M | 11.88M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.97M | 62.46M | 30.12M | 25.01M | 13.69M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.85M | 1.87M | 1.89M | 1.70M | 1.43M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.51M | 59.98M | 27.62M | 22.71M | 11.66M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 65.00K | 369.00K | -280.00K | -245.35M | 3.00M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.17M | - | 39.50M | -13.82M | -20.95M | -27.45M | -13.49M | -19.04M | -13.54M | -6.60M | -5.69M | -8.25M | -1.03M | 12.42M | 11.45M | 59.61M | 27.90M | 268.06M | 8.65M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.11 | - | - | - | 0.13 | -0.10 | -0.08 | - | 0.22 | -0.08 | -0.12 | -0.16 | -0.08 | -0.11 | -0.08 | -0.38 | -0.33 | -0.47 | -0.06 | 0.70 | 0.63 | 3.28 | 1.46 | 13.54 | 0.44 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.44M | - | - | - | 11.68M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 20.38M | 4.48M | 44.51M | 59.29M | 108.62M | 149.24M | 120.24M | 116.88M | 179.28M | 294.28M |
| Operating Income | -112.04M | 35.32M | -86.37M | -99.38M | -89.47M | -91.25M | -51.74M | -69.74M | -79.62M | -72.68M | -69.09M | -28.97M | -12.50M | -55.55M | -20.49M | 24.19M | 125.47M |
| Net Income | -111.55M | 37.89M | -85.97M | -98.84M | -89.03M | -90.91M | -51.46M | -69.22M | -77.99M | -70.48M | -66.89M | -29.74M | -17.91M | -58.57M | -25.09M | 17.48M | 367.02M |
| Diluted EPS | -2.73 | 0.72 | -1.36 | -1.32 | - | - | - | - | - | - | -0.40 | -0.18 | -0.11 | -3.44 | -1.44 | 0.99 | 19.48 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.52M | 23.38M | 33.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 186.69M | 257.11M | 310.04M | 226.06M | 154.13M | 131.75M | 78.13M | 119.11M | 139.11M | 147.57M | 110.38M | - | 134.28M | 117.22M | 163.98M | 513.59M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.90M | 99.27M | 135.10M | 240.17M |
| Cash & Equivalents | 46.01M | 14.72M | 8.88M | 18.63M | 33.48M | 20.85M | 15.20M | 43.46M | 17.63M | 38.29M | 76.32M | 22.52M | 30.37M | - | 24.46M | 32.79M | 56.75M | 40.58M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.12M | 5.52M | 6.00M | 11.51M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.32M | 30.55M | 41.62M | 51.76M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 147.90M | 145.87M | 160.69M | 122.11M |
| Current Liabilities | - | - | 11.33M | 11.53M | 12.20M | 10.29M | 14.03M | 33.80M | 22.59M | 18.34M | 27.73M | 58.21M | 40.84M | - | 65.21M | 53.27M | 63.30M | 99.24M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 10.00M | 20.00M | - | 39.45M | 52.37M | 52.41M | 22.48M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.55M | 60.58M | 59.97M | 53.30M |
| Total Equity | 104.17M | 109.87M | 166.13M | 236.15M | 289.10M | 208.25M | 128.25M | 91.38M | 55.03M | 100.65M | 109.88M | 53.81M | 34.03M | - | -13.62M | -28.64M | 3.29M | 391.48M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.34M | 17.48M | 17.71M | 18.31M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | -23.41M | -75.89M | -77.56M | -58.83M | -41.51M | -52.19M | 5.88M | -73.76M | -5.74M | 31.47M | 75.66M |
| Investing Cash Flow | - | - | - | - | - | - | 44.61M | 24.88M | -19.47M | 24.96M | -23.66M | 47.47M | -80.04M | 72.78M | -4.30M | 4.13M | -92.36M |
| Financing Cash Flow | - | - | - | - | - | - | 7.05M | 25.18M | 117.69M | 71.89M | 11.37M | 12.57M | 62.67M | 6.55M | 18.37M | -11.64M | 601.00K |
| Capital Expenditure | -141.00K | -3.56M | -2.30M | -3.38M | -1.22M | -413.00K | -546.00K | -804.00K | -164.00K | -1.11M | -1.46M | -1.26M | -627.00K | -450.00K | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | -23.96M | -76.69M | -77.72M | -59.93M | -42.97M | -53.45M | 5.25M | -74.21M | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -342.2% | -1,775.6% | -163.3% | -116.5% | -26.7% | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% |
| Net Margin % | - | - | - | - | - | - | - | -339.6% | -1,739.3% | -158.3% | -112.8% | -27.4% | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
| ROE % | -101.5% | 22.8% | -36.4% | -34.2% | -42.7% | -70.9% | -56.3% | -125.8% | -77.5% | -64.1% | -124.3% | -87.4% | - | 430.2% | 87.6% | 531.8% | 93.8% |
| ROCE % | - | 20.1% | -35.2% | -33.4% | -41.5% | -65.1% | -52.8% | -125.6% | -79.0% | -65.3% | -77.3% | -41.7% | - | -80.4% | -32.0% | 24.0% | 30.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.56% | 1.77M | $70.12M |
| 2 | Armistice Capital, LLC | 6.92% | 1.28M | $50.74M |
| 3 | State Street Corporation | 6.05% | 1.12M | $44.41M |
| 4 | Vanguard Capital Management LLC | 4.13% | 764.19K | $30.29M |
| 5 | Acadian Asset Management. LLC | 3.60% | 666.43K | $26.42M |
| 6 | LSV Asset Management | 3.25% | 601.51K | $23.84M |
| 7 | Marshall Wace LLP | 3.23% | 598.38K | $23.72M |
| 8 | American Century Companies Inc | 2.94% | 544.43K | $21.58M |
| 9 | Shaw D.E. & Co., Inc. | 2.41% | 445.68K | $17.67M |
| 10 | Geode Capital Management, LLC | 2.38% | 440.63K | $17.47M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RIGL
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQUWJEdU5GS0FXZ1ZlYmRPd0cyVHZ1bEYwZHNEekVPRTAtaTJjYVVKbndNSnJGRFloUFFwU2ZlWk5GQ2pySjNNS2w5UXN6OW1YVFlGeWx3Y1ByWFVwNHFVeVlkZnE0TGZraUFHNm9EQkFQcGZaSS1FZWpNUXpSd2FLeGpsdm05ZGlzUE5lRj…
Rigel Pharmaceuticals (RIGL) CMO receives 24,400-share RSU equity award with 4-year vesting - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNX1lneG1Mb3N1RVE1RTJKYUxVMjJmWnQ4a3g3aVF0Z1NGTEpPa19DbkdlTEdEUS1rTGJwN2RvRWdWN2hJUUJuM0dTLXpsQkg5dUVDb1Rybl91OE1BazhsUHlnTUZ4em9Qa1FkOVJkRUM4RzZjWC1oeVBNY2ZkcjUtVTA4V1FLWEl1NDZUej…
A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQaUl0VEFNeThOTThJcVFkTXM3VW9TYzVnNTVDakwxcTN2N0Z0aTl3clZqd1VYVlJfbmdTTjlBcjFJRkpRbElSdXhnWUtPZ3JrTGZ1UTBPM2ozOVdyMU9UanpMU1ZIOWRoa1VObnYtT0tZMjRGTkJIMGdGZzZ0NnVKekRrMFlZbi1LeGpxTW…
(RIGL) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQRFVWMWg4NXhrT2luaGRxMnRCMUhRNjJHSHVoblRxdjJfMUlpV0tieVZLY1ZwNUtFWjRVZ2tjdy1KOWU4bzQzZEIxb1pHd3BPWi1OampWZEVFWlN5M0tkdXNDNlZvcUtPTVliZDMybE10OUsyMFM5cDN0bHpPbTNTMHNyRDNJaFhfTEZOWW…
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNS2FZMWNQM3Q1bkNacDdRTHExTXU1ZzJWZ3NycjdmMFZkRHB1Wjd4b2xqN3VtUzN6S0ItbEtvT0xlVVJiZUpIYXpwcEVabUhNQkpTOGlic29DN01aZllzZGZtbkVKUHNZZlZ1a0Z6cDl6V0YyVjVGVWIybkIwaF9NTWVVVWVRVnBiUmN2VT…
$RIGL stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOdUE2Zm95a29uOWcxTDBkRmRRYlV5cFF1MVIxSV8yV0NhWmFHaE8zcWxrZkpwY0JTc3NzZG95Vy16RVhTU0Fxb0Z2cjlib1k5Sm9YaDQtNnFTRTRldVpOQ0FUaXhTY18wT2V1RXdKNUJ3VnZyRXhJUmctSmdnN3Z2N05NdVJnZDBTcFFCMT…
RIGL — Frequently Asked Questions
What is the current share price of Rigel Pharmaceuticals, Inc. (RIGL)?
As of 2026-07-14 21:23 PDT, Rigel Pharmaceuticals, Inc. (RIGL) trades at $41.17 on NasdaqGS. Its 52-week range is $18.80 to $50.96.
What is the market capitalisation of RIGL?
Rigel Pharmaceuticals, Inc. (RIGL) has a market capitalisation of $761.73M on NasdaqGS.
What is the P/E ratio of RIGL?
RIGL trades at a trailing price-to-earnings (P/E) ratio of 2.13. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.52.
Is RIGL a good stock to buy?
This page provides a data-driven analysis of Rigel Pharmaceuticals, Inc. (RIGL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.